Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DFFN

Diffusion Pharmaceuticals (DFFN) Stock Price, News & Analysis

Diffusion Pharmaceuticals logo

About Diffusion Pharmaceuticals Stock (NASDAQ:DFFN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$4.38
$6.60
52-Week Range
N/A
Volume
351,000 shs
Average Volume
10,937 shs
Market Capitalization
$8.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

Receive DFFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DFFN Stock News Headlines

Diffusion Pharmaceuticals Inc.
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.
See More Headlines

DFFN Stock Analysis - Frequently Asked Questions

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) posted its earnings results on Wednesday, November, 10th. The company reported ($9.00) earnings per share for the quarter, missing analysts' consensus estimates of ($3.00) by $6.00.

Shares of Diffusion Pharmaceuticals reverse split on the morning of Thursday, August 17th 2023. The 1-1.5 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 67 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Diffusion Pharmaceuticals investors own include Tonix Pharmaceuticals (TNXP), Onconova Therapeutics (ONTX), OPKO Health (OPK), T2 Biosystems (TTOO), NightHawk Biosciences (NHWK), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
11/10/2021
Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DFFN
Employees
13
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-15,590,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$6.97 per share
Price / Book
N/A

Miscellaneous

Free Float
2,003,000
Market Cap
$8.98 million
Optionable
Not Optionable
Beta
1.78

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:DFFN) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners